Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
- Conditions
- Advanced Triple Negative Breast Cancer (TNBC) With High TAMs
- Interventions
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT02435680
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇹🇷Novartis Investigative Site, Istanbul, Turkey
🇺🇸Massachusetts General Hospital Cancer Center SC, Boston, Massachusetts, United States
AWARE - Chronic Urticaria
- Conditions
- Chronic Urticaria
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT02435238
- Locations
- 🇬🇧
Novartis Investigative Site, Sheffield, United Kingdom
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- Biological: CTL019
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT02435849
- Locations
- 🇺🇸
Childrens Hospital Los Angeles SC CTL019, Los Angeles, California, United States
🇺🇸The Childrens Hospital of Philadelphia CHOP, Philadelphia, Pennsylvania, United States
🇪🇸Novartis Investigative Site, Esplugues De Llobregat, Barcelona, Spain
Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload
- Conditions
- Transfusion-dependent Anemia
- Interventions
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 224
- Registration Number
- NCT02435212
- Locations
- 🇹🇷
Novartis Investigative Site, Izmir, Turkey
🇺🇸Weill Cornell Medical College SC -, New York, New York, United States
🇺🇸Childrens Hospital at Montefiore, Bronx, New York, United States
Study of Efficacy of CDZ173 in Patients With APDS/PASLI
- Conditions
- Common Variable Immunodeficiency (CVID), APDS / PASLI
- Interventions
- Other: Placebo
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT02435173
- Locations
- 🇺🇸
National Institute of Health NIH, Bethesda, Maryland, United States
🇬🇧Novartis Investigative Site, Belfast, United Kingdom
Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT02431481
- Locations
- 🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
🇩🇪Novartis Investigative Site, Berlin, Germany
A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors
- Conditions
- ALK-positive Advanced Tumors
- Interventions
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT02422589
- Locations
- 🇺🇸
Cancer Therapy & Research Center UT Health Science Center SC-4, San Antonio, Texas, United States
🇺🇸Henry Ford Hospital SC, Detroit, Michigan, United States
🇺🇸Karmanos Cancer Institute Oncology Department, Detroit, Michigan, United States
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 726
- Registration Number
- NCT02422615
- Locations
- 🇺🇸
UCLA Medical Center ., Los Angeles, California, United States
🇺🇸Florida Cancer Research Institute Dept of Oncology, Davie, Florida, United States
🇺🇸UF Health Cancer Center at Orlando Health, Orlando, Florida, United States
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
- Conditions
- Hidradenitis Suppurativa (Acne Inversa)
- Interventions
- Drug: PlaceboBiological: CJM112
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT02421172
- Locations
- 🇨🇭
Novartis Investigative Site, Zurich, Switzerland
Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-04-16
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT02418468
- Locations
- 🇭🇰
Novartis Investigative Site, Hong Kong, Hong Kong